GlassScriptPhysician profile
Stephen C Golden
NPI 1093778169
$5,686.76
in general payments reported to CMS, 2019-2025
37 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $282 · 2021: $658 · 2022: $476 · 2023: $1,013 · 2024: $1,402 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $924.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $851.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $702.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $586.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $536.79 | 2021-2025 | |
| Amgen INC. | $281.62 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $263.46 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.49 | 2019-2025 | Xifaxan |
| Allergan, INC. | $185.36 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.30 | 2019-2024 | Jardiance |
| Abbott Laboratories | $116.25 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $105.72 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $98.45 | 2019-2025 | Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $83.44 | 2025 | Rexulti |
| Astellas Pharma US INC | $74.70 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.